Calamos Advisors LLC Buys Shares of 2,700,000 Kenvue Inc. $KVUE

Calamos Advisors LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,700,000 shares of the company’s stock, valued at approximately $46,575,000. Calamos Advisors LLC owned about 0.14% of Kenvue as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Kenvue by 27.1% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 310,686 shares of the company’s stock valued at $5,042,000 after buying an additional 66,192 shares during the last quarter. Renaissance Capital LLC lifted its stake in Kenvue by 55.8% in the third quarter. Renaissance Capital LLC now owns 980,436 shares of the company’s stock valued at $15,912,000 after buying an additional 351,259 shares during the last quarter. Allstate Corp bought a new stake in Kenvue in the third quarter valued at $1,152,000. Aberdeen Group plc lifted its stake in Kenvue by 84.1% in the third quarter. Aberdeen Group plc now owns 1,411,380 shares of the company’s stock valued at $22,914,000 after buying an additional 644,930 shares during the last quarter. Finally, Oak Thistle LLC bought a new stake in Kenvue in the fourth quarter valued at $1,563,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on KVUE shares. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Canaccord Genuity Group raised their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Wednesday, April 8th. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. Finally, Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Price Performance

Shares of KVUE opened at $17.49 on Friday. The firm has a market capitalization of $33.57 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 3.97 and a beta of 0.61. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The stock’s fifty day moving average is $17.82 and its 200-day moving average is $17.15.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share. Equities analysts anticipate that Kenvue Inc. will post 1.1 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s payout ratio is presently 107.79%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.